Lasmiditan

Updates on the use of gepants in migraine 5:51
Updates on the use of gepants in migraine
Nina Yakovlevna Riggins • 4 May 2023
Recent developments in migraine treatment 1:38
Recent developments in migraine treatment
Chia-Chun Chiang • 26 Apr 2023
Do triptans demonstrate better efficacy and/or tolerability than ditans or gepants? 4:39
Do triptans demonstrate better efficacy and/or tolerability than ditans or gepants?
Bojana Žvan • 22 Mar 2022
Moving forward with migraine-specific agents: CGRP & PACAP 1:59
Moving forward with migraine-specific agents: CGRP & PACAP
Zaza Katsarava • 11 Jun 2021
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant 3:02
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
Jessica Ailani • 18 Apr 2021
The evolving landscape of migraine treatment and prevention 3:42
The evolving landscape of migraine treatment and prevention
Uwe Reuter • 22 May 2020
The content of VJNeurology is intended for healthcare professionals